Auxilium Health builds an engineered Aer™ biomaterial platform of bioaerogels intended to resist bacterial attachment while welcoming regenerative cells. The platform spans applications in wound repair, bone regeneration, and localized delivery, with a lead product advancing toward FDA clearance and planned first-in-human studies. The company has attracted researchers and doubled its full-time team over the last year, with several staff relocating to Cleveland. It is headquartered at the Cleveland Clinic's Global Innovation Center and has support from the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster. Financially, Auxilium recently completed an oversubscribed $3.4 million seed round that more than doubled its prior pre-seed financing.

Total raised

$5M

Funding rounds

3

Latest round

Seed

Latest activity

Jul 2026